Last reviewed · How we verify
perindopril + moxonidine
Perindopril inhibits ACE to reduce angiotensin II formation, while moxonidine activates central imidazoline receptors to reduce sympathetic outflow, together lowering blood pressure through complementary pathways.
Perindopril inhibits ACE to reduce angiotensin II formation, while moxonidine activates central imidazoline receptors to reduce sympathetic outflow, together lowering blood pressure through complementary pathways. Used for Hypertension.
At a glance
| Generic name | perindopril + moxonidine |
|---|---|
| Sponsor | Sergey V. Nedogoda |
| Drug class | ACE inhibitor + imidazoline receptor agonist combination |
| Target | ACE (angiotensin-converting enzyme) and imidazoline-1 receptors |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Perindopril is an ACE inhibitor that prevents conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion. Moxonidine is a selective imidazoline-1 receptor agonist that decreases central sympathetic nervous system activity. The combination provides synergistic antihypertensive effects targeting both the renin-angiotensin-aldosterone system and sympathetic nervous system.
Approved indications
- Hypertension
Common side effects
- Dry cough
- Dizziness
- Fatigue
- Headache
- Hyperkalemia
Key clinical trials
- Comparative Effects of Moxonidine on Bone Metabolism, Vascular and Cellular Aging in Hypertensive Postmenopausal Women (NA)
- Moxonidine + Perindopril in Hypertensive Patients With Metabolic Syndrome (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- perindopril + moxonidine CI brief — competitive landscape report
- perindopril + moxonidine updates RSS · CI watch RSS
- Sergey V. Nedogoda portfolio CI